GLP-1 dosage charts on TikTok: what they get wrong

What did @peppy.k2 actually say?

Honestly, not much that can be fact-checked. The spoken transcript is motivational filler: "It's me versus me this time. This is very, very personal." There are no dosage numbers, no drug names, no clinical claims in the audio. The video's caption, however, tells a different story. "These r some dosage charts" paired with the hashtags #glp1 and #peptide strongly implies the video is displaying dosage information on screen, even if the creator isn't verbalizing it.

This is a pattern worth flagging. Creators frequently embed the substantive medical content in text overlays, charts, or graphics while keeping verbal audio vague or motivational. That structure lets them share dosing information while maintaining a layer of plausible deniability. The transcript alone can't be evaluated as medical content because it contains none. But the caption explicitly describes dosage charts for a category of regulated drugs, which is where the real concern lives.

Does the science back this up?

There is no scientific claim in the transcript to evaluate, so let's focus on what the video appears to be doing: presenting GLP-1 dosage information outside a clinical context. That is a problem regardless of whether the charts themselves are numerically accurate.

FDA-approved GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) have specific, label-defined titration schedules established through phase 3 clinical trials. For semaglutide, the STEP trials (Wilding et al., 2021, New England Journal of Medicine) used a structured 16-week titration to 2.4 mg weekly. For tirzepatide, the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) used escalating doses from 2.5 mg up to 15 mg over months. These schedules exist because dose escalation timing directly affects tolerability and adverse event rates. A chart that compresses or alters those schedules is not just inaccurate. It is potentially harmful.

What did they get wrong (or right)?

The creator didn't get anything technically wrong in speech because they said nothing clinical. Credit where it's due: "It's me versus me" is not a medical claim. But the framing of this video, a lifestyle creator posting dosage charts for prescription peptides while using motivational audio as cover, is a real issue.

What is almost certainly wrong is the implied premise: that a social media dosage chart is an appropriate or safe source for titrating a GLP-1 medication. These drugs carry real risks. Semaglutide and tirzepatide are both associated with gastrointestinal adverse events, and there are ongoing investigations into gastroparesis risk (Sodhi et al., 2023, JAMA). Thyroid C-cell tumor risk remains a labeled warning. Pancreatitis is a documented concern. Titrating these medications without a prescriber involved is not a lifestyle choice. It is a safety issue. The caption's casual tone, "These r some dosage charts," does not match the clinical weight of what's being shared.

What should you actually know?

GLP-1 dosing is not a one-size-fits-all chart situation. The titration schedules on drug labels were tested in controlled trials with medical monitoring. Your starting dose, escalation pace, and maximum dose depend on your kidney function, GI tolerance, cardiovascular history, and whether you're using the drug for diabetes management versus weight loss. Those variables don't appear on a TikTok graphic.

Compounded semaglutide and tirzepatide, which many people accessing these drugs outside traditional prescribers are using, add another layer of complexity. Compounded formulations are not FDA-approved and may differ in concentration, excipients, and stability from brand-name products. A dosage chart built for Wegovy does not automatically apply to a compounded version, and vice versa. If you are using any GLP-1 medication, your dosing plan should come from a licensed prescriber reviewing your individual health history, not from a video captioned with "these r some dosage charts."